# BHVN — Biohaven Ltd · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BHVN  
**Sources:** 24  
**Published:** 2026-10-12  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bhvn-biohaven-ltd-catalysts-narrative-risks-7180

---

## Snapshot

Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company in the biotechnology sector, trading around US$12 (52-week range US$7.48–18.57) with an intraday market capitalization of approximately US$1.83 billion and a beta of 3.20 [[22]](https://finance.yahoo.com/quote/BHVN/). The company is pre-revenue with a large accumulated loss (net income of roughly −US$587 million trailing twelve months; EPS of −US$4.56) and carries a heavy balance-sheet leverage (debt/equity near 2,430%) [[22]](https://finance.yahoo.com/quote/BHVN/). Below is a critical synthesis of recent developments, the bull/bear debate, risks, and the calendar, drawing primarily on material from the last ~1–3 months.

## Recent catalysts (approximately July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bhvn-biohaven-ltd-catalysts-narrative-risks-7180 (free to sign up)._
